Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Contact: Study coordinator (Xiaolin MM GE, PhD) · doctorsxl@163.com · 13951818797

Study leads

Xiaolin MM GE
Study Director
The First Affiliated Hospital with Nanjing Medical University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Resectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma · Unresectable Locally Advanced Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Tokyo, Japan